As AMPK is known to play a central role in both anabolism and catabolism, influencing levels/functions of both metabolites and proteins, it is reasonable to suggest that aldometanib, via activation of AMPK, clears the way for mobilization of immune cells, particularly CD8+ T cells, to induce cytotoxicity in the tumor tissues. This evidence concerns the gene PRKAA2 and neoplasm.